Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odalasvir + AL-335 + simeprevir
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose **oral combination of three direct-acting antiviral agents**—the NS5A inhibitor odalasvir, the uridine nucleotide analog prodrug polymerase inhibitor AL-335 (also called adafosbuvir), and the NS3/4A protease inhibitor simeprevir—investigated for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotypes 1, 2, 4, 5, and 6. The combination demonstrated high sustained virologic response rates (SVR12 and SVR24 ≥97%) and was well-tolerated in Phase 2 trials in non-cirrhotic and cirrhotic, treatment-naive and experienced patients. Each component targets a different viral protein: odalasvir inhibits HCV NS5A, AL-335 is metabolized to an active nucleoside disrupting HCV NS5B polymerase, and simeprevir blocks HCV NS3/4A protease activity[1][2][3][4][6][7][8].
- Brand names
- JNJ-4178JNJ4178JNJ 4178
- Other names
- adafosbuvir + odalasvir + simeprevirJNJ-4178JNJ4178JNJ 4178
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on odalasvir + AL-335 + simeprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odalasvir + AL-335 + simeprevir.